» Articles » PMID: 36111490

COVID-19 Patient Fibrinogen Produces Dense Clots with Altered Polymerization Kinetics, Partially Explained by Increased Sialic Acid

Overview
Publisher Elsevier
Specialty Hematology
Date 2022 Sep 16
PMID 36111490
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Thrombogenicity is a known complication of COVID-19, resulting from SARS-CoV-2 infection, with significant effects on morbidity and mortality.

Objective: We aimed to better understand the effects of COVID-19 on fibrinogen and the resulting effects on clot structure, formation, and degradation.

Methods: Fibrinogen isolated from COVID-19 patients and uninfected subjects was used to form uniformly concentrated clots (2 mg/ml), which were characterized using confocal microscopy, scanning electron microscopy, atomic force microscopy, and endogenous and exogenous fibrinolysis assays. Neuraminidase digestion and subsequent NANA assay were used to quantify sialic acid residue presence; clots made from the desialylated fibrinogen were then assayed similarly to the original fibrinogen clots.

Results: Clots made from purified fibrinogen from COVID-19 patients were shown to be significantly stiffer and denser than clots made using fibrinogen from noninfected subjects. Endogenous and exogenous fibrinolysis assays demonstrated that clot polymerization and degradation dynamics were different for purified fibrinogen from COVID-19 patients compared with fibrinogen from noninfected subjects. Quantification of sialic acid residues via the NANA assay demonstrated that SARS-CoV-2-positive fibrinogen samples contained significantly more sialic acid. Desialylation via neuraminidase digestion resolved differences in clot density. Desialylation did not normalize differences in polymerization, but did affect rate of exogenous fibrinolysis.

Discussion: These differences noted in purified SARS-CoV-2-positive clots demonstrate that structural differences in fibrinogen, and not just differences in gross fibrinogen concentration, contribute to clinical differences in thrombotic features associated with COVID-19. These structural differences are at least in part mediated by differential sialylation.

Citing Articles

Deconstructing fibrin(ogen) structure.

Risman R, Sen M, Tutwiler V, Hudson N J Thromb Haemost. 2024; 23(2):368-380.

PMID: 39536819 PMC: 11786978. DOI: 10.1016/j.jtha.2024.10.024.


Dietary Antioxidants and Natural Compounds in Preventing Thrombosis and Cardiovascular Disease.

Giurranna E, Nencini F, Bettiol A, Borghi S, Argento F, Emmi G Int J Mol Sci. 2024; 25(21).

PMID: 39519009 PMC: 11546393. DOI: 10.3390/ijms252111457.


Post-translational modifications of fibrinogen: implications for clotting, fibrin structure and degradation.

Nencini F, Bettiol A, Argento F, Borghi S, Giurranna E, Emmi G Mol Biomed. 2024; 5(1):45.

PMID: 39477884 PMC: 11525374. DOI: 10.1186/s43556-024-00214-x.


Fibrin clot permeability (Ks) in patients on left ventricular assist device.

Kuczaj A, Skrzypek M, Hudzik B, Kaczmarski J, Pawlak S, Hrapkowicz T Sci Rep. 2024; 14(1):20193.

PMID: 39214985 PMC: 11364743. DOI: 10.1038/s41598-024-69665-0.


Comprehensive Analysis of the Role of Fibrinogen and Thrombin in Clot Formation and Structure for Plasma and Purified Fibrinogen.

Risman R, Belcher H, Ramanujam R, Weisel J, Hudson N, Tutwiler V Biomolecules. 2024; 14(2).

PMID: 38397467 PMC: 10886591. DOI: 10.3390/biom14020230.


References
1.
Valladolid C, Martinez-Vargas M, Sekhar N, Lam F, Brown C, Palzkill T . Modulating the rate of fibrin formation and clot structure attenuates microvascular thrombosis in systemic inflammation. Blood Adv. 2020; 4(7):1340-1349. PMC: 7160269. DOI: 10.1182/bloodadvances.2020001500. View

2.
Renzi S, Landoni G, Zangrillo A, Ciceri F . MicroCLOTS pathophysiology in coronavirus disease 2019. Korean J Intern Med. 2020; 38(4):570-571. PMC: 10338241. DOI: 10.3904/kjim.2020.336. View

3.
Whitworth H, Sartain S, Kumar R, Armstrong K, Ballester L, Betensky M . Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-C. Blood. 2021; 138(2):190-198. PMC: 8079262. DOI: 10.1182/blood.2020010218. View

4.
Brown A, Hannan R, Timmins L, Fernandez J, Barker T, Guzzetta N . Fibrin Network Changes in Neonates after Cardiopulmonary Bypass. Anesthesiology. 2016; 124(5):1021-31. PMC: 4837010. DOI: 10.1097/ALN.0000000000001058. View

5.
Dang C, Shin C, Bell W, Nagaswami C, Weisel J . Fibrinogen sialic acid residues are low affinity calcium-binding sites that influence fibrin assembly. J Biol Chem. 1989; 264(25):15104-8. View